Skip to content
Menu

Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $23

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.

Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.

Read at benzinga.com